Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis. — CFSMEATLAS
Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis.
Kerr, Jonathan R, Gough, John, Richards, Selwyn C M et al. · The Journal of general virology · 2010 · DOI
Quick Summary
This study looked at whether parvovirus B19 (a common virus) plays a role in ME/CFS, particularly in patients with joint pain. While ME/CFS patients and healthy people had similar rates of past B19 infection, researchers found that ME/CFS patients were much more likely to have specific antibodies suggesting the virus wasn't being cleared properly from their body. Interestingly, patients with these antibodies were more likely to report chronic joint pain.
Why It Matters
This research provides evidence that a subset of ME/CFS patients may have persistent parvovirus B19 infection that their immune systems cannot fully clear, which could contribute to ongoing symptoms like joint pain. Understanding viral persistence in ME/CFS could lead to better diagnostic testing and potentially targeted treatment approaches for patients with this subtype.
Observed Findings
41.5% of ME/CFS patients were positive for anti-B19 NS1 IgG compared to only 7% of healthy controls (odds ratio 9.42)
Of the 83 ME/CFS patients with NS1 antibodies, 73.5% reported chronic joint pain
Parvovirus B19 DNA was detectable in serum of 11 ME/CFS patients but in none of the 200 healthy controls
B19 seroprevalence (indicating past infection) was similar between ME/CFS patients and controls (75% vs 78%)
NS1 antibody positivity was associated with higher expression levels of ME/CFS-associated genes NHLH1 and GABPA
Inferred Conclusions
Although B19 infection rates are similar between ME/CFS patients and the general population, ME/CFS patients may have impaired immune control of the virus
The presence of NS1 antibodies suggests chronic or severe B19 infection in ME/CFS patients, which may not be adequately cleared
Persistent or poorly controlled parvovirus B19 infection may contribute to joint pain symptoms in a subset of ME/CFS patients
Remaining Questions
Does treating persistent parvovirus B19 infection in ME/CFS patients improve their symptoms, particularly joint pain?
What specific immune mechanism prevents proper clearance of B19 in ME/CFS patients despite evidence of immune response?
What This Study Does Not Prove
This study does not prove that parvovirus B19 causes ME/CFS, only that some ME/CFS patients have markers of persistent or poorly controlled B19 infection. The presence of these antibodies and viral DNA may be a consequence of ME/CFS-related immune dysfunction rather than the cause. The study cannot determine whether treating B19 infection would improve ME/CFS symptoms.